71 results
Page 2 of 4
8-K
EX-99.1
yn6kaqcexp4wbwy3h
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
7sx4un wczl
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
51qohbcyn010wy2 07
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
m1nlrm ope5
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
ip2ktbw uajh3efyl6u
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
l3astla0wjmi4ha ce
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
ld77ot92
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
h2jf5zqmbxa
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
zbq6w
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
424B5
5t9ga2 jfcxjqj0un
5 May 21
Prospectus supplement for primary offering
4:01pm